Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients

Phase 1

Terminated

• Conditions: End Stage Renal Disease
• Interventions: Drug: pravastatin

• Registration Number: NCT00571194
• Lead Sponsor: Arkansas Children's Hospital Research Institute

Brief Summary

Many children with end stage renal disease develop hyperlipidemia. HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, such as pravastatin, are typical treatments for hyperlipidemia. However, we do not know how pravastatin is metabolized in patients on dialysis. This study is designed to provide preliminary pharmacokinetic data for pravastatin in pediatric patients on peritoneal dialysis.

Detailed Description

This is a single-dose pilot study to evaluate the pharmacokinetic profile of pravastatin in 7 pediatric and adolescent subjects ranging from 12 months to 16 years of age who are on dialysis. The study group will be comprised of healthy children receiving continuous cycling peritoneal dialysis (CCPD). Pravastatin dosing will be 10 mg in all subjects. Blood, urine, and dialysate samples will be obtained over a 24-hour period post-dose for measurement of pravastatin concentrations. Safety evaluations will include adverse events (AEs), physical examination, vital signs, and clinical laboratory evaluations.

Study Timeline

• Study Start: 2007-09
• Study First Submitted: 2007-12-10
• Study First Submitted QC: 2007-12-10
• Study First Posted: 2007-12-11
• Primary Completion: 2009-05
• Study Completion: 2009-05
• Results First Submitted: 2011-02-15
• Status Verified: 2017-01
• Results First Submitted QC: 2017-01-26
• Last Update Submitted: 2017-01-26
• Results First Posted: 2017-03-15
• Last Update Posted: 2017-03-15

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

1. Patients from 12 months to 18 years of age.

2. Patients with end stage renal disease who receive continuous cycling peritoneal dialysis.

3. signed informed consent

4. Physical exam demonstrates no abnormalities that would make this study medically hazardous to the subject.

Exclusion Criteria

1. Any clinically significant unstable medical condition or chronic disease other than those associated with ESRD.
2. Any clinically significant illness within 10 days or receiving single-sdoe of study medication
3. History of rhabdomyolysis
4. Clinically significant liver disease or history of malabsorption or previous gastrointestinal surgery that could effect drug absorption or metabolism.
5. Clinical laboratory abnormalities: Aspartate aminotransferase (AST), Alanine Aminotransferase (ALT), Creatine phosphokinase(CPK) > 2.5 times upper limit of normal; hemoglobin < 8.5 g.dL.
6. Known hypersensitivity to pravastatin
7. Unwilling to have blood samples drawn
8. Has taken a HMG-CoA reductase inhibitor in the last week -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
peritoneal dialysis (CCPD)	pravastatin	PK profile of pravastatin

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics	24 hours

Trial Locations

Locations (1)

Arkansas Children's Hospital; 🇺🇸 Little Rock, Arkansas, United States